We tested the hypothesis that the 5HT1DR, the primary antinociceptive target of triptans, is differentially distributed in tissues responsible for migraine pain. The density of 5HT1DR was quantified in tissues obtained from adult female rats with Western blot analysis. Receptor location was assessed with immunohistochemistry. The density of 5HT1DR was significantly greater in tissues known to produce migraine-like pain (i.e. circle of Willis and dura) than in structures in which triptans have no antinociceptive efficacy (i.e. temporalis muscle). 5HT1DRlike immunoreactivity was restricted to neuronal fibres, where it colocalized with calcitonin gene-related peptide and tyrosine hydroxylase immunoreactive fibres. These results are consistent with our hypothesis that the limited therapeutic profile of triptans could reflect its differential peripheral distribution and that the antinociceptive efficacy reflects inhibition of neuropeptide release from sensory afferents. An additional site of action at sympathetic efferents is also suggested. ᮀ Headache, triptans, trigeminal ganglion neuron, sympathethic postganglionic neuron
Introduction
Triptans, serotonin type 1B/1D receptor (5HT1B/1DR) agonists, are one of the most effective drugs used to treat migraine pain (1) . Interestingly, the therapeutic efficacy of these compounds appears to be restricted to migraine pain. For example, in animal behavioural studies, triptans have no impact on baseline nociceptive threshold assessed with application of stimuli to somatic tissue (2) and fail to reverse sciatic nerve injury-induced decreases in paw withdrawal or vocalization thresholds (3) . Similarly, naratriptan fails to attenuate noxious stimulationevoked activity in spinal dorsal horn neurons (4) . In contrast, naratriptan dose-dependently inhibited activity in trigeminal dorsal horn neurons evoked with noxious stimuli applied to the dura (4) . Moreover, in clinical studies sumatriptan does not alleviate myofacial pain from temporalis muscle (5) and is of little clinical benefit to patients suffering from atypical facial pain (6) . The limited therapeutic efficacy of these compounds is striking, however, in light of evidence indicating that 5HT 1DR protein is present in cell bodies of both trigeminal and dorsal root ganglia (7, 8) .
Mechanisms underlying the therapeutic efficacy of triptans are also debated, with data in support of vasoconstriction, inhibition of neurotransmission in the central nervous system, and inhibition of peripheral neurotransmitter release from primary afferents. Initially, triptans were administered because it was thought that they could reverse the painful vasodilation associated with migraine by producing potent vasoconstriction (1) . It was later discovered that the 5HT 1BR was responsible for this vasoconstriction, and that this receptor subtype was located postsynaptically in vascular smooth muscle (9) . However, the absence of a temporal correlation between changes in vascular tone and migraine pain argues against the vascular hypothesis of triptan antinociception and for a dominant role of 5HT1DR activation (10) . Because the 5HT1DR is expressed in primary afferent neurons and not in peripheral tissues or second-order neurons (7) (8) (9) , the prevailing hypothesis is that the antinociceptive efficacy of triptans reflects the inhibition of transmitter release from primary afferents (11) (12) (13) (14) , in particular the neuropeptide calcitonin gene-related peptide (CGRP). Consistent with this hypothesis, there is evidence that triptans inhibit inflammation and CGRP release from peripheral nerve terminals (13) (14) (15) . There is also evidence that triptans may reduce central neurotransmitter release primarily from afferents via a presynaptic mechanism (16) .
There is general agreement that migraine pain ultimately reflects increased activity in afferents innervating the dura mater. Dural afferents have received a considerable amount of attention, given evidence that stimulation of fibres innervating the middle meningeal artery (MMA) produces pain that mimics pain felt during a migraine (17) and evidence that dural inflammation and release of CGRP from dural afferents can be blocked by sumatriptan (13, 14) . However, nerve fibres innervating purely vascular structures may also play a significant role in migraine pain. Stimulation of arteries proximal to the circle of Willis, such as the intracranial internal carotid arteries and middle cerebral arteries, produces migraine-like pain in neurosurgical patients (17) similar to that seen with stimulation of meningeal arteries. There are additional data to suggest that head pain can occur during carotid artery dissection, presumably via activation of trigeminovascular afferents, and that this pain may be treated with sumatriptan (18) . Although there is evidence of 5HT 1DR in fibres innervating the dura (7, 8) , the presence of this receptor in other migraine-associated tissues (MATs) has yet to be investigated.
In the face of evidence suggesting that the peripheral 5HT1DR contributes significantly to the therapeutic efficacy of triptans, the clinical selectivity of these drugs may be explained by differential distribution of this receptor in fibres innervating MATs vs. non-MATs. The observation that the 5HT1DR is located in only 20-40% of cell bodies (8, 15) is consistent with the possibility that this receptor does not have a uniform peripheral distribution. Therefore, we hypothesized that the selectivity of these drugs reflects a higher density of the 5HT 1DR in peripheral nerve fibres innervating MATs (common carotid artery, circle of Willis and dura mater) compared with non-migraine-associated vascular (external carotid artery) and non-vascular (temporalis muscle) tissues. To test this hypothesis, the density of 5HT 1DR was quantified with Western blot analysis of whole-cell lysates taken from dura, temporalis muscle, common, internal, external carotid arteries, circle of Willis and ganglia whose fibres innervate craniofacial structures. To determine where the 5HT 1DR was located in peripheral tissues, diaminobenzidine (DAB) immunohistochemistry of 5HT1DR in whole mounted tissues from dura, extracranial and intracranial arteries was examined. Colocalization of the 5HT1DR with CGRP and tyrosine hydroxylase (TH) was also examined in the dura using immunofluorescence.
Materials and methods

Animals
Adult female Sprague Dawley rats (Harlan, Indianapolis, IN, USA) weighing 150-250 g were used for all experiments. Rats were housed two per cage in the University of Pittsburgh animal facility on a 12:12 light : dark schedule with food and water freely available. Prior to all procedures, animals were deeply anaesthetized with an intraperitoneal injection (1 ml/kg) of rat cocktail containing ketamine (55 mg/kg), xylazine (5.5 mg/kg) and acepromazine (1.1 mg/kg). Experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and performed in accordance with National Institutes of Health guidelines for the use of laboratory animals in research.
Quantification of 5HT 1D R using Western blotting
The supratentorial dura mater was collected with the MMA, superior sagittal sinus and the nerves that innervate them. Additionally, the entire length of the common carotid artery was isolated from surrounding tissues by blunt dissection and separated from the accompanying jugular vein and vagus nerve. The internal, external carotid arteries and the circle of Willis were collected after these structures were dissected free from large accompanying nerves and surrounding tissues by blunt dissection. The belly of the temporalis muscle was also collected without the attached tendons. Tissues were then homogenized in RIPA buffer [50 mM Tris, 150 mM NaCl, 1 mM ethylenediamine tetraaceticacid, 1% NP 40, 0.1% sodium dodecyl sulphate (SDS)] containing protease inhibitors (6.8 mg/ml apoprotinin, 4 mg/ml leupeptin, 4 mg/ml pepstatin, 4 mg/ml trypsin inhibitor, 4 mg/ml E64, 2 mM phenylmethylsulphonyl fluoride, 2 mM Na3VO4) on ice. Protein concentration was determined using a BioRad RCDC Protein Assay kit, and 150 mg of total protein per sample was run on 10% SDSpolyacrylamide gel electrophoresis gel. Protein was transferred to nitrocellulose membrane and blots were blocked with 5% milk and then incubated with rabbit polyclonal 5HT1DR antibody (1:250; Abcam, Cambridge, MA, USA) overnight. Blots were stripped and reprobed with goat polyclonal PGP9.5 antibody (1:5000; Abcam) as a marker for neuronal tissue, mouse monoclonal b-actin (1:5000; Abcam) and mouse monoclonal glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (1:5000; Abcam) as loading controls. For immunodetection, blots were incubated in peroxidaseconjugated secondary antibody (1:10 000; Jackson ImmunoResearch, West Grove, PA, USA) and visualized following chemiluminescence reaction (ECL plus; GE Healthcare, Milwaukee, WI, USA) with an LAS3000 CCD camera (FujiFilm Life Science, Stamford, CT, USA).
The band intensity from each tissue in each blot was quantified using MultiGauge software (FujiFilm Life Science). Intensities for 5HT 1DR immunoreactive bands were normalized either to b-actin or to PGP9.5 (as an estimate of 5HT1DR relative to innervation density). Since comparisons were made between blots, these ratios were also normalized to that for a tissue common to each blot (i.e. dura or internal carotid artery). Data were expressed as the mean Ϯ S.E.M. of the relative ratios.
Controls for Western blots
To determine the extent of non-specific binding of the primary antibody, the 5HT1DR antibody was preincubated with peptide fragments corresponding to amino acids 1-18 and 251-267 of the rat 5HT1DR (GenScript, Scotch Plains, NJ, USA) at a concentration of 20 mg/ml. To determine if there was nonspecific binding of the secondary antibody, the primary antibody was omitted from Western blots.
Localization of 5HT 1D R in peripheral tissue
Immunohistochemistry Rats were transcardially perfused with ice-cold 1¥ phosphate-buffered saline (pH 7.2) and ice-cold 4% paraformaldehyde. Tissues were post-fixed with 4% paraformaldehyde from 1 to 12 h. For DAB immunoperoxidase immunohistochemistry, free-floating tissues were incubated in 0.3% peroxide for 30 min, blocked with 2% normal goat serum at room temperature and then incubated in rabbit polyclonal 5HT 1DR primary antibody (1:500; Abcam) at 4°C for 3 days. Tissues were incubated with biotinylated goat antirabbit IgG (1:200; Vector Laboratories Vectastain kit, Burlingame, CA, USA) for 2 h at room temperature and avidin-biotin-peroxidase complex (Vector Laboratories Vectastain kit) for 30 min at room temperature. DAB (1 mg/ml with 2.5% nickel sulphate) was used to visualize 5HT 1DR like immunoreactive (5HT1DR LI) fibres. Tissues were mounted on slides and, following ethanol dehydration, coverslipped with Permount media (Fisher Scientific, Waltham, MA, USA).
For immunofluorescence staining of whole mounts, free-floating tissues were blocked with 10% normal donkey serum at room temperature for 1 h and then incubated in a combination of rabbit polyclonal 5HT 1DR (1:250; Abcam) and sheep polyclonal CGRP (1:500; Abcam) or sheep TH antibodies (1:500; Chemicon International, Temecula, CA, USA) for 48-72 h at room temperature. Free-floating tissues were then incubated in donkey antirabbit Cy3 (1:200; Jackson ImmunoResearch) and donkey antisheep Cy2 (1:500; Jackson ImmunoResearch)conjugated secondary antibodies at room temperature for 2 h.
Superior cervical and trigeminal ganglia were removed from animals following perfusion fixation, and tissues were submerged in 30% sucrose overnight, frozen in OCT (Tissue Tek, Torrence, CA, USA) and cut in 16-mm sections. Sectioned tissues were blocked with 5% normal donkey serum, incubated in 5HT 1DR (1:250), CGRP (1:500) or TH (1:500) antibody overnight at room temperature and then in donkey antirabbit or sheep Cy2 (1:200; Jackson ImmunoResearch)-conjugated secondary antibody for 2 h at room temperature.
For retrograde labelling of trigeminal ganglion neurons innervating the dura, a craniotomy was made in the area overlying the superior sagittal sinus, leaving the underlying dura intact and exposed for application of retrograde tracer 1,1′dioctadecyl-3,3,3′ ,3′ -tetramethylindocarbocyanine perchloride (DiI; 170 mg/ml in dimethylsulphoxide diluted 1:10 in saline). A single droplet of DiI was applied onto the exposed dura using a 30-G needle attached to a Hamilton syringe by catheter tubing. A dental rubber dam was placed on the exposed Craniofacial distribution of 5HT 1DR 935 dura and secured to the cranium with superglue adhesive. An acrylic cap made from dental orthodontic resin was used to replace the removed cranium and the incision closed with sutures. Animals received intramuscular injections of penicillin G (100 000 U/kg) and buprenorphine (0.03 mg/kg) following surgery. Ten days following application of DiI, animals were sacrificed.
Immunofluorescence staining was visualized on a Leica DM4000B (Bannockburn, IL, USA) microscope and images captured using a Leica DFC300 FX camera. Nerve fibres and cell bodies were considered immunoreactive when the immunofluorescent signal was clearly greater than that obtained when the primary antibody was omitted. For counts of 5HT1DR immunoreactive cell bodies from superior cervical ganglia, three sections were examined per animal of tissue obtained from two animals. Data were expressed as the percentage of total cell bodies showing 5HT 1DR immunoreactivity per section in a field under ¥200 magnification and the average percentage was generated for each animal.
Statistical analysis
One-way analysis of variance (ANOVA) was used to assess differences between tissues. Tukey or Dunn's tests were used for post-hoc comparisons between these groups. For comparisons between relative ratios taken from Western blots run for superior cervical and trigeminal ganglia, a t-test was performed. P Յ 0.05 was considered to be statistically significant.
Results
The density of 5HT 1D R LI does not vary among migraine-associated tissues
To determine if there are differences between MATs with respect to the distribution of 5HT1DR protein, Western blots of whole-cell lysates from dura, common carotid artery and circle of Willis were analysed. Total protein concentration was quantified from each sample, and the same amount of protein (150 mg) was loaded per lane (Fig. 1A) . Densitometric analysis of blots from eight animals, normalized to the internal carotid artery, revealed no statistically significant difference (P > 0.05) in the amount of 5HT 1DR LI between MATs (Fig. 1B) . Use of b-actin as a loading control ( Fig. 1A ,C) confirmed that this was not due to differences in loading or transfer of proteins.
Data from previous studies suggest that the 5HT 1DR is present only in neural tissue (7) (8) (9) . There is also evidence of differences between target tissues with respect to density of innervation (19, 20) . Therefore, we sought to assess the density of 5HT1DR LI among MATs after taking into account differences in innervation density. The neural marker PGP9.5 was used to assess innervation density (Fig. 1A) . Among MATs, there was a significantly greater amount (P < 0.05, n = 8) of PGP9.5 in circle of Willis compared with dura ( Fig. 1D ). However, when normalized to PGP9.5, there still remained no significant difference between MATs with respect to the 5HT 1DR : PGP9.5 ratio (P > 0.05, n = 8, Fig. 1E ).
The density of 5HT 1D R is greater in MATs than in non-MATs
Since we were able to quantify 5HT1DR LI in MATs, we then asked if the clinical selectivity of triptan therapy could reflect differences in the density of 5HT 1DR between MATs and non-MATs. The external carotid artery was used as a vascular non-MAT and the temporalis muscle was used as a non-vascular non-MAT. One-way ANOVA of the dataset, including non-MATs, indicated a significant (P < 0.05) effect of target tissue. Post-hoc analysis revealed that the significant effect of target tissue on 5HT1DR LI was due to a significantly lower level of 5HT1DR LI in external carotid artery compared with common carotid artery and circle of Willis, and a significantly lower level of 5HT 1DR LI in temporalis muscle compared with common carotid artery, circle of Willis and dura (P < 0.05, n = 8, Fig. 1B ). The significant differences between external carotid artery, common carotid artery and circle of Willis remained when data were normalized to b-actin (Fig. 1C ). Because b-actin was undetectable in striated muscle (Fig. 1A) , GAPDH was used as a loading control (data not shown). The relatively high level of GAPDH in striated muscle highlights difficulties associated with assessing relative protein levels between distinct tissue types, but argues against the suggestion that the relatively low density of 5HT 1DR LI detected in muscle was due to problems with loading or transfer of proteins.
One-way ANOVA of the dataset, including non-MATs, again revealed a significant (P < 0.05) effect of target tissue with respect to levels of PGP9.5 LI. Post-hoc analysis indicated the density of PGP9.5 in temporalis muscle was significantly (P < 0.05) greater than that in dura (Fig. 1D ). Pooled data from eight animals indicated that the relative density of 5HT1DR LI normalized to PGP9.5 in the external carotid artery was significantly lower than that in the common carotid artery and circle of Willis (P < 0.05; Fig. 1E ). Likewise, the density of 5HT1DR LI in temporalis muscle was significantly lower than that in the common carotid artery, circle of Willis or dura (P < 0.05; Fig. 1E ).
Pre-absorption of the 5HT1DR antibody with the peptide it was raised against was used to confirm the specificity of the immunoreactivity. This eliminated the two bands present in all tissues (approximately 60 and 62 kDa) and the high-molecularweight band (approximately 65 kDa) restricted to the dura (control: Fig. 1A) . Similar results were obtained following omission of the primary antibody (data not shown).
5HT 1D R LI is primarily localized to neuronal fibres innervating peripheral tissues
To confirm that 5HT1DR LI detected with Western blot analysis was associated with neural tissue, localization of the receptor was assessed with immunohistochemistry. We observed 5HT1DR LI in nerve fibres innervating the rat dura mater. There did not appear to be any 5HT1DR LI in the meningeal arteries or resident mast cells. 5HT1DR LI fibres of the dura mater ran along with the MMA. These fibres branched with arterial bifurcations. There were also 5HT1DR LI fibres that intersected the MMA and traversed the meninges in a direction perpendicular to the MMA and parallel to the superior sagittal sinus ( Fig. 2A) . 5HT1DR LI was present in large nerve trunks and smaller fibres (Fig. 2B ). In addition, we observed 5HT1DR LI nerve fibres in segments of the extracranial and intracranial cerebrovasculature, including the external carotid artery and circle of Willis (Fig. 2C ,D, respectively).
5HT 1D R LI is colocalized with CGRP LI in the dura mater
Given evidence of 5HT1DR-mediated inhibition of CGRP release (11, 14) , we sought to determine the extent to which there is colocalization of the receptor with this primary afferent neuropeptide in peripheral tissue. Double-labelling experiments revealed the presence of both 5HT 1DR LI and CGRP LI within dural nerve bundles (Fig. 3A,B ). However, there were also nerve bundles that displayed 5HT1DR LI that did not overlap with CGRP LI (Fig. 3C) . Although CGRP is commonly used a marker for peptidergic sensory neurons, neuropeptide immunoreactivity, including CGRP LI, has been detected in subpopulations of sympathetic postganglionic neurons (SPGNs) (21) . Therefore, in order to assess the possibility that a portion of the CGRP LI fibres innervating the dura were from SPGNs, we probed the superior cervical ganglion (SCG) for the presence of CGRP LI. Trigeminal ganglia (TG) from the same rats were collected and run in parallel as a positive control. We were unable to detect the presence of CGRP LI in SCG from two rats, despite CGRP LI in small-and medium-diameter TG neurons (Fig. 4) . The absence of CGRP LI in rat SCG is consistent with previous reports indicating that although CGRP LI is present in human, feline and canine SCG, it is undetectable in SCG from rat or guinea pig (21) (22) (23) .
5HT 1D R LI is present in sympathetic postganglionic neurons innervating the dura mater
Considering recent evidence that sympathetic activity may modulate afferent signalling in the dura mater (24) and the dense innervation of the dural parenchyma and MMA by TH LI fibres, (presumably arising from the superior cervical ganglia: Fig. 5A ), we determined if the nonpeptidergic 5HT1DR LI fibres could be sympathetic efferent. Double-labelling experiments revealed colocalization of 5HT1DR LI with TH in a number of dural fibres (Fig. 5B ).
To confirm that this staining was indeed from the SCG, the presence of 5HT1DR LI was assessed in SCG. Again, TG from the same rats were run in parallel (Fig. 6A) . In six sections of SCG from two rats, 9% of cell bodies displayed 5HT1DR LI (Fig. 6B) . To assess the density of 5HT1DR in SCG relative to that in TG, Western blots of whole-cell lysates generated from both tissues were processed. Pooled data from five rats normalized to PGP9.5 suggested that, on average, there is a twofold higher density of 5HT1DR in the TG compared with the SCG (P = 0.012, Fig. 6C ).
Previous reports have indicated that there is a subpopulation of sensory neurons with TH LI (25, 26) . Therefore, in order to determine the extent to Craniofacial distribution of 5HT1DR 939 which TH LI fibres innervating the dura could arise from the TG, we probed TG retrogradely labelled from the dura with DiI, for the presence of TH LI. Four sections each from TG obtained from two rats were analysed. TH LI was clearly detectable in a small subpopulation (3-4%) of TG neurons ( Fig. 7A ). However, none of the 52 TG neurons that were retrogradely labelled with DiI displayed TH LI (Fig. 7B ).
Discussion
The present study was designed to test the hypothesis that the selective therapeutic efficacy of triptans reflects a high density of 5HT1DR in tissues underlying migraine pain. We observed that there was no difference between MATs with respect to the relative density of 5HT1DR. However, the relative density of 5HT1DR was lower in non-MATs (i.e. temporalis muscle) than in MATs. 5HT1DR LI was restricted to nerve fibres innervating peripheral tissues, where it was colocalized in many fibres with the neuropeptide CGRP. 5HT1DR LI was also colocalized with TH in many fibres that appeared to arise from the superior cervical ganglia.
5HT 1D R LI is present in a number of MATs
Our conclusion that the distribution of the 5HT1DR is similar between MATs is based on Western blot data showing no significant differences in the amounts of 5HT1DR in the common carotid artery, circle of Willis or dura, whether data were analysed as a function of total protein, normalized to loading controls such as b-actin, or normalized to innervation density estimated with PGP9.5. To justify the normalization of 5HT 1DR to PGP9.5, we explored the possibility that non-neuronal components of peripheral tissues might contain the 5HT1DR. Consistent with previous reports demonstrating that 5HT1DR mRNA and protein are not found in intracranial arteries but rather in the perivascular nerves that innervate them (7, 9) , our data also indicate that 5HT1DR LI is restricted to nerve fibres. It is always possible that we have overestimated density of 5HT1DR in the common carotid artery and circle of Willis due to contamination with fibres of passage. However, we suggest that such an overestimation is minimal based on our anatomical results (Fig. 2) , which were consistent with a terminal pattern of innervation and the observation that there is no rostral-caudal trend to the pattern of distribution (i.e. higher levels found in proximal structures such as common carotid artery and lower levels found in distal structures such as circle of Willis).
Prior studies have indicated that activation of nerve fibres innervating the dura mater plays a critical role in generating migraine pain. afferents innervating dural blood vessels produced migraine-like pain (17) . Furthermore, inflammatory mediators released during the ictal period of migraine are able to increase activity of dural afferents and their second-order neurons in the trigeminal nucleus following exogenous application to the dura (27, 28) . Importantly, these inflammation-induced changes in dural afferent activity can be blocked by sumatriptan. Sumatriptan is also able to decrease plasma protein extravasation in the dura and CGRP release from dural afferents. Although little attention has been paid to other blood vessels of the head and neck and the afferents that innervate them, our results demonstrating high density of the 5HT1DR in nerve fibres innervating the common carotid artery and circle of Willis suggest that other populations of vascular afferents, in addition to those innervating the dura mater, may contribute to migraine pain. This conclusion is supported by immunohistochemistry demonstrating innervation of intracranial arteries by nociceptive-like afferents containing both CGRP and substance P (29), by clinical observations that endovascular procedures resulting in the stimulation of several arteries within the cranial vault are painful (30) , and early studies demonstrating that stimulation of proximal branches of the circle of Willis produces migraine-like pain (17) .
In addition, there are data suggesting that head pain occurs during dissection of the carotid artery, presumably via activation of trigeminovascular afferents; and that this pain may be treated with sumatriptan (18) .
The density of 5HT 1D R is greater in MATs than in non-MATs
Although there are few reports to suggest that triptans may inhibit peripheral inflammation irrespective of tissue type, (8, 31) , as summarized in the Introduction, there are a number of studies demonstrating selectivity in the antinociceptive efficacy of triptans (4) (5) (6) 32) . Our data indicating the density of 5HT 1DR is lower in temporalis muscle than common carotid artery, circle of Willis or dura are consistent with our hypothesis and suggest that the lower density of receptor in nerve fibres innervating the temporalis muscle may have contributed to failure of triptans in the clinical trial of myofacial pain arising from the temporalis muscle (5) .
There may be unique processing of the 5HT1DR within the dura Interestingly, three distinct 5HT1DR LI bands (56, 60 and 62 kDa) were detected in our Western blots of lysates from dura and other vascular tissues. The lower-molecular-weight band was not detected in the temporalis muscle, the TG or the SCG. An additional higher-molecular-weight band (65 kDa) was detected in the dura. All four bands were eliminated by pre-absorption of the primary antibody, suggesting the bands contain a protein with a specific 5HT 1DR epitope. That the 65-kDa band was absent in the trigeminal ganglion or in lysates taken from the brainstem (data not shown) argues against a splice variant, and for a post-translational modification in the peripheral target. Inspection of the 5HT1DR protein sequence reveals several sites for post-translational modification, specifically, N-glycosylation (33) . Thus, there may be posttranslational processing of the receptor as the receptor is being trafficked or at the peripheral terminal innervating the end organ. The fact that we observed this higher-molecular-weight band only in the dura suggests an alternative mechanism for the therapeutic specificity of triptans.
5HT 1D R LI in peptidergic primary afferent fibres
Previous data suggest that expression of 5HT1DR in the cell bodies of sensory neurons is restricted to a subpopulation of neurons expressing CGRP, with 75-90% of 5HT1DR+ neurons double-labelled with CGRP (8, 15, 34) . Consistent with these reports, we observed colocalization of 5HT1DR and CGRP in dural fibres. This overlap in the periphery supports the hypothesis that triptan inhibition of peripheral CGRP release is via a direct mode of action (i.e. on the afferent terminal). However, our data also suggest 5HT1DR is present in non-peptidergic fibres. At least some of these fibres appear to be SPGNs, given colocalization of 5HT1DR LI with TH LI in the dura mater and the presence of 5HT1DR LI in cell bodies of the SCG. That these receptors on SPGNs are functional is suggested by the observation that 5HT1DR agonists inhibit sympathetically mediated pressor and tachycardic responses (35, 36) .
A role for SPGNs in migraine?
The presence of 5HT1DR LI in SPGNs raises the possibility that the therapeutic efficacy of triptans reflects an action of these neurons innervating the dura mater or other vascular tissues. Given the hypothesis that migraine pain may be caused by painful dilation of dural blood vessels (17), one might predict that an increase in sympathetic efferent activity would result in pain relief in association with vasoconstriction. However, there is also evidence that the SPGN may contribute to peripheral inflammation. For example, sympathetic efferents have been shown to release adenosine triphosphate (37) and prostaglandin (PG) E 2 (38) , which would contribute to primary afferent activation and sensitization and therefore neurogenic inflammation and pain. Importantly, recent evidence indicates that sympathomimetics increase basal levels of PGE2 in rat dura mater (24) . In summary, there remain a number of other possible factors that might contribute to the clinical selectivity of triptans, including potential differences in bioavailability and pharmacology of peripherally located receptors, contributions of central spinal and supraspinal receptors, and the minimum number of 5HT1DR-containing fibres needed to appreciate differences in pain perception. Nevertheless, our results are consistent with the hypothesis that the therapeutic efficacy of triptans may reflect, at least in part, a selective pattern of 5HT1DR expression, with the highest density of receptor in the innervation of structures likely to contribute to migraine pain. Although the location of this receptor in peptide-containing nerve fibres innervating peripheral tissues is consistent with the suggestion that pain relief reflects inhibition of CGRP release from peripheral afferent terminals, the presence of the receptor on SPGN terminals raises the possibility that the therapeutic efficacy of triptans may also reflect an action on efferent fibres. Teasing out the relative importance of these two mechanisms of action may enable the development of more selective and effective treatments for migraine.
